Skip to main content
Premium Trial:

Request an Annual Quote

LexaGene Plans C$2M Private Placement

NEW YORK (GenomeWeb) — LexaGene announced today that it is planning a non-brokered private placement of up to roughly C$2 million ($1.5 million) worth of stock and warrants.

Beverly, Massachusetts-based LexaGene — which trades on the Toronto Stock Exchange — said it will offer up to 3 million units at C$.65 apiece. Each unit will consist of one common share and a warrant to purchase one common share at C$.85 for a period of 15 months from the date the unit was issued.

LexaGene said it intends to use the proceeds of the transaction to fund beta development of its LX Analyzer technology, which uses microfluidic PCR for pathogen detection, and for marketing the technology to the food safety and veterinary diagnostics industries.

In July, LexaGene closed a bought deal financing to raise C$5.8 million. It also disclosed that it is evaluating its technology for use in cancer diagnostic sample preparation.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.